VG Life Sciences granted key composition of matter patent

(Viral Genetics, Inc.) VG Life Sciences, Inc., a biotechnology company developing therapies for autoimmune and infectious diseases, has been issued an important composition of matter patent covering methods for modulating immune system function through the targeting of CLIP. The US patent covers the targeted peptide technology underlying VG Life Sciences' VG1177, a synthetic peptide which has the ability to displace CLIP that plays a key role in chronic inflammation and autoimmune diseases, including HIV/AIDS, hypertension, preeclampsia and TBI.
Source: EurekAlert! - Biology - Category: Biology Source Type: news